Quarterly report pursuant to sections 13 or 15(d)

Condensed Consolidated Statement of Operations

v2.4.0.8
Condensed Consolidated Statement of Operations (USD $)
 3 Months Ended
Mar. 31, 2014
Mar. 31, 2013
Revenue:    
Medical devices $ 526,753 $ 332,919
Engineering services 534,958 363,330
Total revenue 1,061,711 696,249
Cost of revenue:    
Cost of medical devices 330,125 232,563
Cost of engineering services 252,103 347,214
Total cost of revenue 582,228 579,777
Gross profit 479,483 116,472
Operating expenses:    
Sales and marketing 1,531,382 1,216,043
Research and development 768,542 921,706
General and administrative 2,071,443 1,133,454
Total operating expenses 4,371,367 3,271,203
Loss from operations (3,891,884) (3,154,731)
Other income (expense):    
Interest expense (426,603) (639,113)
Loss on warrant liability (77,436,700)   
Interest income 1,400 1,264
Other expense, net (11,572) (4,174)
Total other expense, net (77,873,475) (642,023)
Net loss $ (81,765,359) $ (3,796,754)
Basic and diluted net loss per share $ (1.22) $ (0.18)
Weighted-average number of shares used in computing basic and diluted net loss per share amounts 67,072,057 20,636,529